Mangalam Drugs (India) Performance
| MANGALAM | 105.02 1.10 1.06% |
The company secures a Beta (Market Risk) of 0.24, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Mangalam Drugs' returns are expected to increase less than the market. However, during the bear market, the loss of holding Mangalam Drugs is expected to be smaller as well. At this point, Mangalam Drugs And has a negative expected return of -0.43%. Please make sure to verify Mangalam Drugs' maximum drawdown, kurtosis, day median price, as well as the relationship between the potential upside and daily balance of power , to decide if Mangalam Drugs And performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Mangalam Drugs And has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's essential indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 10:1 | Ex Dividend Date 2017-12-21 | Last Split Date 2016-11-29 |
1 | Additional Considerations Required While Assessing Mangalam Drugs Organics Strong Earnings - Simply Wall St | 11/21/2024 |
| Begin Period Cash Flow | 26.8 M |
Mangalam |
Mangalam Drugs Relative Risk vs. Return Landscape
If you would invest 13,985 in Mangalam Drugs And on August 24, 2024 and sell it today you would lose (3,483) from holding Mangalam Drugs And or give up 24.91% of portfolio value over 90 days. Mangalam Drugs And is generating negative expected returns and assumes 2.064% volatility on return distribution over the 90 days horizon. Simply put, 18% of stocks are less volatile than Mangalam, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Mangalam Drugs Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mangalam Drugs' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mangalam Drugs And, and traders can use it to determine the average amount a Mangalam Drugs' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2095
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MANGALAM |
Estimated Market Risk
| 2.06 actual daily | 18 82% of assets are more volatile |
Expected Return
| -0.43 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.21 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Mangalam Drugs is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mangalam Drugs by adding Mangalam Drugs to a well-diversified portfolio.
Mangalam Drugs Fundamentals Growth
Mangalam Stock prices reflect investors' perceptions of the future prospects and financial health of Mangalam Drugs, and Mangalam Drugs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mangalam Stock performance.
| Return On Equity | -0.0631 | ||||
| Return On Asset | 0.005 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 2.74 B | ||||
| Shares Outstanding | 15.83 M | ||||
| Price To Book | 1.24 X | ||||
| Price To Sales | 0.46 X | ||||
| Revenue | 3.67 B | ||||
| Gross Profit | 1.17 B | ||||
| EBITDA | 174.95 M | ||||
| Net Income | (90.72 M) | ||||
| Cash And Equivalents | 917.4 M | ||||
| Total Debt | 984.92 M | ||||
| Book Value Per Share | 85.79 X | ||||
| Cash Flow From Operations | 39.13 M | ||||
| Earnings Per Share | (4.03) X | ||||
| Total Asset | 3.34 B | ||||
| Retained Earnings | 975.89 M | ||||
About Mangalam Drugs Performance
By analyzing Mangalam Drugs' fundamental ratios, stakeholders can gain valuable insights into Mangalam Drugs' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Mangalam Drugs has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Mangalam Drugs has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Mangalam Drugs is entity of India. It is traded as Stock on NSE exchange.Things to note about Mangalam Drugs And performance evaluation
Checking the ongoing alerts about Mangalam Drugs for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mangalam Drugs And help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mangalam Drugs And generated a negative expected return over the last 90 days | |
| The company reported the revenue of 3.67 B. Net Loss for the year was (90.72 M) with profit before overhead, payroll, taxes, and interest of 1.17 B. | |
| About 55.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Additional Considerations Required While Assessing Mangalam Drugs Organics Strong Earnings - Simply Wall St |
- Analyzing Mangalam Drugs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mangalam Drugs' stock is overvalued or undervalued compared to its peers.
- Examining Mangalam Drugs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mangalam Drugs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mangalam Drugs' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mangalam Drugs' stock. These opinions can provide insight into Mangalam Drugs' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Mangalam Stock analysis
When running Mangalam Drugs' price analysis, check to measure Mangalam Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangalam Drugs is operating at the current time. Most of Mangalam Drugs' value examination focuses on studying past and present price action to predict the probability of Mangalam Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangalam Drugs' price. Additionally, you may evaluate how the addition of Mangalam Drugs to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |